arrow
G

Gregory D. Cascino

University of Salerno
H指数:67
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture

超过29,000名癫痫患者的ghis荟萃分析确定了26个风险基因座和亚型特异性遗传结构

2023-08-3143
OAAI
Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy An Analysis of a Complex Comorbidity

新诊断的局灶性癫痫患者的情绪和焦虑障碍以及自杀行为复杂合并症的分析

2023-03-1427
OA
Multimodal mapping of regional brain vulnerability to focal cortical dysplasia

局灶性皮质发育不良的区域脑脆弱性的多模态映射

BRAIN
IF11.7
2023-02-289
OA
TMEM161B regulates cerebral cortical gyration, Sonic Hedgehog signaling, and ciliary structure in the developing central nervous system

TMEM161B在发育中的中枢神经系统中调节大脑皮层回旋,声波刺猬信号和睫状结构

2023-01-2012
OAAI
Lack of clinically relevant differences in safety and pharmacokinetics after second-dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: A population analysis

4小时内滴鼻地西泮用于丛集性癫痫急性治疗后,安全性和药代动力学缺乏临床相关差异: 人群分析

2022-04-198
OAAI
Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: Results from a phase 3, open-label, repeat-dose safety study

使用第二剂量的Valtoco®(地西epa鼻喷雾剂) 在初始剂量后24小时内用于院外癫痫发作群: 来自3期,开放标签,重复剂量安全性研究的结果

2022-02-0215
OAAI
Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy

地西泮鼻喷雾剂治疗癫痫发作群的3期、长期、开放标签、重复剂量安全性研究的最终结果

2021-08-2153
OAAI